Search

Hans Kristensen, Director of the Nuclear Information Project, Federation of American Scientists, Washington DC and co-author of “The Growing Threat of Nuclear War and the Role of the Health Comm

Audio Journal of Oncology, January 2, 2017 COPENHAGEN—Patients with metastatic non-small cell lung cancers (NSCLC) expressing the programmed cell-death ligand 1 (PD-L1) protein responded better to ini

COPENHAGEN—Longer progression free survival (PFS) was achieved in patients with ALK-rearranged non-small cell lung cancer (NSCLC) previously treated with crizotinib randomised to treatment with the se

The Audio Journal of Oncology Reporting from the 2016 Congress of the European Society of Medical Oncology COPENHAGEN—The anti-PD-L1 (programmed cell death ligand-1) immunotherapy agent atezolizumab e

COPENAGEN—Adding the PD-1 (programmed cell death protein 1) antibody pembrolizumab to standard first-line chemotherapy with carboplatin and pemetrexed for previously-untreated patients with advanced n

COPENHAGEN—In a phase I study reported at the 2016 congress of the European Society for Medical Oncology (ESMO) six out of 15 patients with resectable early non-small cell lung cancer had “major

Audio Journal of Oncology COPENHAGEN, Denmark—In a phase 1b study patients with previously untreated stage IV pancreatic cancer responded or derived “clinical benefit” from a regimen in wh

COPENHAGEN, Denmark—Marked prolongation of progression free survival (PFS) in all groups of patients with platinum-sensitive recurrent ovarian cancer was reported at the European Society for Medical O

DESCRIPTION COPENHAGEN, Denmark—The efficacy of endocrine therapy in breast cancer was improved—in the MONALEESA-2 study—by the addition of the cyclin-dependent kinase (CDK) 4/6 inhibitor ribociclib t

COPENHAGEN, Denmark—Checkpoint inhibition prolonged life when used as adjuvant therapy among patients with fully resected stage III malignant melanoma in the EORTC 18071 randomized phase III compariso

Side effects from early treatment of low and intermediate risk prostate cancer need to be balanced agains the new finding that mortality is no different during the first ten years irrespective of the

Active monitoring seems to be the safest and most comfortable option for most men with localised prostate cancer according to findings of the big randomised ProtecT study from the UK. Surgery and rad